StockNews.AI
TECH
StockNews.AI
35 days

Spear Bio Announces Strategic Partnership with Bio-Techne to Accelerate the Deployment of Its Next-Generation Immunoassay Technology

1. Bio-Techne partners with Spear Bio to enhance biomarker detection. 2. New SPEAR UltraDetect™ immunoassays target neurodegenerative disease biomarkers. 3. The partnership boosts access to high-sensitivity disease detection technologies. 4. Spear Bio's technology offers significantly higher sensitivity than current platforms. 5. This collaboration enhances clinical trial capabilities and early disease diagnosis.

6m saved
Insight
Article

FAQ

Why Bullish?

Strategic partnerships often lead to increased revenue and market presence, as seen with prior similar collaborations in biotech, which typically result in a stock price increase for involved companies.

How important is it?

The partnership significantly enhances Bio-Techne's product offerings in a high-growth market, likely influencing investor sentiment and stock performance positively.

Why Long Term?

The collaboration aims to improve significant areas like neurodegenerative disease detection, which takes time to yield results but could fundamentally transform the market in the long run.

Related Companies

TECHSPEAR
WOBURN, Mass.--(BUSINESS WIRE)--Spear Bio, a biotechnology company pioneering homogeneous ultrasensitive immunoassay technology, is pleased to announce a strategic distribution partnership with Bio-Techne Corporation (NASDAQ: TECH), a global leading provider of innovative reagents, instruments, and solutions for life-science research and clinical diagnostics. The partnership significantly expands global access to Spear Bio’s groundbreaking SPEAR UltraDetect™ immunoassays, focusing initially on the neurology research market. The introductory SPEAR UltraDetect offering targets biomarkers pivotal to neurodegenerative diseases, such as phosphorylated tau 231 (pTau 231), phosphorylated tau 217 (pTau 217), glial fibrillary acidic protein (GFAP), and neurofilament light (Nf‑L). This partnership follows Bio-Techne's participation in Spear Bio’s $45 million Series A funding round in 2024. Early detection of protein biomarkers is essential for understanding historically challenging disease mechanisms, developing early interventions, and advancing clinical trials. Spear Bio’s Successive Proximity Extension Amplification Reaction (SPEAR) platform, based on breakthrough technology licensed from Harvard University, and amplified using conventional qPCR instrumentation, offers sensitivity two to three orders of magnitude higher than current immunoassay platforms. "Partnering with Spear Bio marks an exciting step in our mission to advance biomarker detection in neurodegenerative disease research," said Will Geist, President of Bio-Techne’s Protein Sciences Segment. "By leveraging Bio-Techne’s global reach and immunoassay expertise with Spear Bio’s ultrasensitive technology, we are equipping researchers with innovative tools to detect and study critical biomarkers with unmatched precision and sensitivity." With Bio-Techne’s global reach, Spear Bio is well-positioned to accelerate the deployment of its next-generation assay technology, enabling researchers to detect biomarkers in historically challenging conditions. Spear Bio’s initial focus is neurodegenerative diseases, with the technology relevant for inflammation, oncology and additional fields. In addition, Spear Bio’s advanced detection technology expands applications in high-growth markets, including early neurodegenerative disease diagnosis, enhancing patient access to critical interventions. “Our strategic partnership with Bio-Techne represents a transformative opportunity for neurodegenerative disease research,” said Feng Xuan, PhD, Founder and CEO of Spear Bio. “By combining Bio-Techne’s global distribution network and market leadership with Spear Bio’s next-generation immunoassay technology, we are empowering researchers worldwide to investigate earlier disease mechanisms, improve patient stratification in clinical trials, and accelerate the development of new treatments for neurological disorders.” This partnership underscores the promise of Spear Bio’s SPEAR technology and reinforces Bio-Techne’s commitment to advancing biomarker detection. Learn more about Spear Bio and Bio-Techne About Bio-Techne Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit https://www.bio-techne.com or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube. About Spear Bio Founded in 2021 and headquartered in Woburn, Massachusetts, Spear Bio is dedicated to its mission of revolutionizing biomarker research and diagnostics through innovation and accessibility. Leveraging its unique homogeneous assay format, SPEAR technology consistently delivers highly sensitive and precise protein measurements. Spear Bio envisions a future where high-performance assays democratize access to critical insights, accelerating progress in research and medicine worldwide. To learn more about the company, please visit the Spear Bio website.

Related News